Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

Plasma levels of C-type lectin REG3α and gut damage in people with HIV.

Isnard S, Ramendra R, Dupuy FP, Lin J, Fombuena B, Kokinov N, Kema I, Jenabian MA, Lebouché B, Costiniuk CT, Ancuta P, Bernard NF, Silverman MS, Lakatos PL, Durand M, Tremblay C, Routy JP; Montreal primary HIV infection study; Canadian cohort of HIV+ slow progressors; Canadian HIV and Aging cohort groups.

J Infect Dis. 2019 Aug 23. pii: jiz423. doi: 10.1093/infdis/jiz423. [Epub ahead of print]

PMID:
31504638
2.

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape.

LeBlanc JF, Wiseman D, Lakatos PL, Bessissow T.

World J Gastroenterol. 2019 Aug 14;25(30):4158-4171. doi: 10.3748/wjg.v25.i30.4158. Review.

3.

Can We Say No to the 'Nocebo Effect' in Inflammatory Bowel Diseases?

Gonczi L, Lakatos PL.

J Crohns Colitis. 2019 Sep 19;13(9):1095-1096. doi: 10.1093/ecco-jcc/jjz098. No abstract available.

PMID:
31329840
4.

Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis.

Hart L, Chavannes M, Kherad O, Maedler C, Mourad N, Marcus V, Afif W, Bitton A, Lakatos PL, Brassard P, Bessissow T.

J Crohns Colitis. 2019 Jun 10. pii: jjz107. doi: 10.1093/ecco-jcc/jjz107. [Epub ahead of print]

PMID:
31314884
5.

Patient and general population values for luminal and perianal fistulising Crohn's disease health states.

Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL.

Eur J Health Econ. 2019 Jun;20(Suppl 1):91-100. doi: 10.1007/s10198-019-01065-y. Epub 2019 May 17.

6.

High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance.

Singh K, Al Khoury A, Kurti Z, Gonczi L, Reinglas J, Verdon C, Kohen R, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

J Crohns Colitis. 2019 Sep 27;13(10):1343-1350. doi: 10.1093/ecco-jcc/jjz066.

PMID:
30918959
7.

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease.

Chao CY, Lemieux C, Restellini S, Afif W, Bitton A, Lakatos PL, Wild G, Bessissow T.

Saudi J Gastroenterol. 2019 May-Jun;25(3):159-166. doi: 10.4103/sjg.SJG_566_18.

8.

Risk of Malignant Cancers in Inflammatory Bowel Disease.

Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P.

J Crohns Colitis. 2019 Sep 27;13(10):1302-1310. doi: 10.1093/ecco-jcc/jjz058.

PMID:
30874294
9.

Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?

Gonczi L, Ilias A, Kurti Z, Lakatos PL.

Curr Pharm Des. 2019;25(1):13-18. doi: 10.2174/1381612825666190312112900.

PMID:
30864504
10.

Reply.

Lovasz BD, Ilias A, Gonczi L, Lakatos PL.

J Gastrointestin Liver Dis. 2019 Mar;28(1):131-132. doi: 10.15403/jgld.2014.1121.281.rpl. No abstract available.

11.

[The role of fecal calprotectin in the diagnosis and treatment of gastrointestinal diseases].

Iliás Á, Rózsa FP, Gönczi L, Lovász BD, Kürti Z, Lakatos PL.

Orv Hetil. 2019 Mar;160(9):322-328. doi: 10.1556/650.2019.31289. Hungarian.

PMID:
30798622
12.

Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre.

Gonczi L, Kurti Z, Verdon C, Reinglas J, Kohen R, Morin I, Chavez K, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

J Crohns Colitis. 2019 Sep 19;13(9):1138-1147. doi: 10.1093/ecco-jcc/jjz035.

PMID:
30793162
13.

Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development.

King JA, Underwood FE, Panaccione N, Quan J, Windsor JW, Kotze PG, Ng SC, Ghosh S, Lakatos PL, Jess T, Panaccione R, Seow CH, Ben-Horin S, Burisch J, Colombel JF, Loftus EV Jr, Gearry R, Halfvarson J, Kaplan GG.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):287-295. doi: 10.1016/S2468-1253(19)30013-5. Epub 2019 Feb 12.

PMID:
30765267
14.

Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S.

Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.

15.

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.

Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL.

Clin Gastroenterol Hepatol. 2019 Jan 8. pii: S1542-3565(19)30009-6. doi: 10.1016/j.cgh.2018.12.036. [Epub ahead of print]

PMID:
30630103
16.

Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic.

Reinglas J, Restellini S, Gonczi L, Kurti Z, Verdon C, Nene S, Kohen R, Afif W, Bessissow T, Wild G, Seidman E, Bitton A, Lakatos PL.

Dig Liver Dis. 2019 Mar;51(3):340-345. doi: 10.1016/j.dld.2018.11.013. Epub 2018 Dec 3.

PMID:
30591367
17.

Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review.

Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1265-1275.e8. doi: 10.1016/j.cgh.2018.12.021. Epub 2018 Dec 21. Review.

PMID:
30583048
18.

Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes.

Ilias A, Lovasz BD, Gonczi L, Kurti Z, Vegh Z, Sumegi LD, Golovics PA, Rudas G, Lakatos PL.

J Gastrointestin Liver Dis. 2018 Dec;27(4):391-397. doi: 10.15403/jgld.2014.1121.274.ocm.

19.

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study.

Burisch J, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, Andersen KW, Andersen V, Kaimakliotis IP, Fumery M, Gower-Rousseau C, Girardin G, Valpiani D, Goldis A, Brinar M, Čuković-Čavka S, Oksanen P, Collin P, Barros L, Magro F, Misra R, Arebi N, Eriksson C, Halfvarson J, Kievit HAL, Pedersen N, Kjeldsen J, Myers S, Sebastian S, Katsanos KH, Christodoulou DK, Midjord J, Nielsen KR, Kiudelis G, Kupcinskas L, Nikulina I, Belousova E, Schwartz D, Odes S, Salupere R, Carmona A, Pineda JR, Vegh Z, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group.

J Gastroenterol Hepatol. 2019 Jun;34(6):996-1003. doi: 10.1111/jgh.14563. Epub 2019 Jan 21.

PMID:
30562421
20.

High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.

Chao CY, Al Khoury A, Aruljothy A, Restellini S, Wyse J, Afif W, Bitton A, Lakatos PL, Bessissow T.

Dig Dis Sci. 2019 Feb;64(2):518-523. doi: 10.1007/s10620-018-5358-z. Epub 2018 Nov 16.

PMID:
30446928
21.

Reply to Letter on: 'Risk Factors Associated With Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis'.

Balram B, Battat R, Al-Khoury A, D'Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T.

J Crohns Colitis. 2019 Mar 30;13(4):536-537. doi: 10.1093/ecco-jcc/jjy176. No abstract available.

PMID:
30371761
22.

Herpes Zoster Incidence in Inflammatory Bowel Disease Patients: A Population-Based Study.

Côté-Daigneault J, Bessissow T, Nicolae MV, Nie R, Bitton A, Lakatos PL, Brassard P.

Inflamm Bowel Dis. 2019 Apr 11;25(5):914-918. doi: 10.1093/ibd/izy311.

PMID:
30295818
23.

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.

Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D'Incà R, Salupere R, Chetcuti Zammit S, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P; Epi-IBD Group.

J Crohns Colitis. 2019 Feb 1;13(2):198-208. doi: 10.1093/ecco-jcc/jjy154.

PMID:
30289522
24.

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.

Bálint A, Rutka M, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Szepes Z, Nagy F, Palatka K, Lovas S, Végh Z, Kürti Z, Csontos Á, Miheller P, Nyári T, Bor R, Milassin Á, Fábián A, Szántó K, Lakatos PL, Molnár T, Farkas K.

Expert Opin Biol Ther. 2018 Nov;18(11):1181-1187. doi: 10.1080/14712598.2018.1530758. Epub 2018 Oct 9.

PMID:
30277084
25.

Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Balram B, Battat R, Al-Khoury A, D'Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T.

J Crohns Colitis. 2019 Jan 1;13(1):27-38. doi: 10.1093/ecco-jcc/jjy143.

PMID:
30247650
26.

Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, Banai J, Herszényi L, Cserni T, Molnár T, Péntek M, Palatka K.

Qual Life Res. 2019 Jan;28(1):141-152. doi: 10.1007/s11136-018-2003-4. Epub 2018 Sep 17.

PMID:
30225788
27.

Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives.

Bitton A, Vutcovici M, Lytvyak E, Kachan N, Bressler B, Jones J, Lakatos PL, Sewitch M, El-Matary W, Melmed G, Nguyen G; QI consensus group; Promoting Access and Care through Centers of Excellence-PACE program).

Inflamm Bowel Dis. 2019 Jan 10;25(2):403-409. doi: 10.1093/ibd/izy259.

PMID:
30169582
28.

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.

Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL.

World J Gastroenterol. 2018 Aug 28;24(32):3567-3582. doi: 10.3748/wjg.v24.i32.3567. Review.

29.

Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply.

Goncalves J, Magro F, Danese S, Lakatos PL, Ben-Horin S.

Aliment Pharmacol Ther. 2018 Sep;48(5):575-576. doi: 10.1111/apt.14860. No abstract available.

PMID:
30156326
30.

Biosimilars in ulcerative colitis: When and for who?

Ilias A, Gonczi L, Kurti Z, Lakatos PL.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:35-42. doi: 10.1016/j.bpg.2018.05.003. Epub 2018 May 26. Review.

PMID:
30060937
31.

Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries.

Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV Jr, Moum B, Tang W, Ng SC, Gearry R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C, Kaplan GG, Burisch J, Colombel JF.

Gastroenterology. 2018 Oct;155(4):1079-1089.e3. doi: 10.1053/j.gastro.2018.06.043. Epub 2018 Jun 27.

PMID:
29958857
32.

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

Strohl M, Gonczi L, Kurt Z, Bessissow T, Lakatos PL.

World J Gastroenterol. 2018 Jun 14;24(22):2363-2372. doi: 10.3748/wjg.v24.i22.2363. Review.

33.

Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.

Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, Afif W, Lakatos PL, Bitton A, Cocciolillo S, Ghali P, Bessissow T, Sebastiani G.

Inflamm Bowel Dis. 2019 Jan 1;25(1):124-133. doi: 10.1093/ibd/izy200.

PMID:
29889226
34.

Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.

Goncalves J, Santos M, Acurcio R, Iria I, Gouveia L, Matos Brito P, Catarina Cunha-Santos A, Barbas A, Galvão J, Barbosa I, Aires da Silva F, Alcobia A, Cavaco M, Cardoso M, Delgado Alves J, Carey JJ, Dörner T, Eurico Fonseca J, Palmela C, Torres J, Lima Vieira C, Trabuco D, Fiorino G, Strik A, Yavzori M, Rosa I, Correia L, Magro F, D'Haens G, Ben-Horin S, Lakatos PL, Danese S.

Aliment Pharmacol Ther. 2018 Sep;48(5):507-522. doi: 10.1111/apt.14808. Epub 2018 Jun 5.

PMID:
29873091
35.

Endoscopic management of Crohn's strictures.

Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G.

World J Gastroenterol. 2018 May 7;24(17):1859-1867. doi: 10.3748/wjg.v24.i17.1859. Review.

36.

Progress with infliximab biosimilars for inflammatory bowel disease.

Kurti Z, Gonczi L, Lakatos PL.

Expert Opin Biol Ther. 2018 Jun;18(6):633-640. doi: 10.1080/14712598.2018.1469620. Epub 2018 Apr 29. Review.

PMID:
29688797
37.

Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.

Restellini S, Chao CY, Lakatos PL, Aruljothy A, Aziz H, Kherad O, Bitton A, Wild G, Afif W, Bessissow T.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1531-1538. doi: 10.1093/ibd/izy044.

PMID:
29668893
38.

The Use of Balloon-assisted Enteroscopy at a Large Volume Centre: A Retrospective Analysis.

Benmassaoud A, Sasson MS, Pamphile JC, Martel M, Lakatos PL, Barkun AN, Soulellis C, Bessissow T.

J Can Assoc Gastroenterol. 2018 Mar 27;1(1):33-39. doi: 10.1093/jcag/gwy007. eCollection 2018 Apr.

39.

Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M.

United European Gastroenterol J. 2018 Mar;6(2):310-321. doi: 10.1177/2050640617708952. Epub 2017 May 8.

40.

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database.

Kurti Z, Ilias A, Gonczi L, Vegh Z, Fadgyas-Freyler P, Korponay G, Golovics PA, Lovasz BD, Lakatos PL.

BMC Gastroenterol. 2018 Jan 30;18(1):23. doi: 10.1186/s12876-018-0746-6.

41.

Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.

Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, Salupere R, Pedersen N, Kjeldsen J, D'Incà R, Valpiani D, Schwartz D, Odes S, Olsen J, Nielsen KR, Vegh Z, Lakatos PL, Toca A, Turcan S, Katsanos KH, Christodoulou DK, Fumery M, Gower-Rousseau C, Chetcuti Zammit S, Ellul P, Eriksson C, Halfvarson J, Magro FJ, Duricova D, Bortlik M, Fernandez A, Hernández V, Myers S, Sebastian S, Oksanen P, Collin P, Goldis A, Misra R, Arebi N, Kaimakliotis IP, Nikuina I, Belousova E, Brinar M, Cukovic-Cavka S, Langholz E, Munkholm P; Epi-IBD group.

Gut. 2018 Jan 23. pii: gutjnl-2017-315568. doi: 10.1136/gutjnl-2017-315568. [Epub ahead of print]

PMID:
29363534
42.

Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M.

Sci Rep. 2018 Jan 10;8(1):399. doi: 10.1038/s41598-017-18622-1.

43.

Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.

Benmassaoud A, Al-Taweel T, Sasson MS, Moza D, Strohl M, Kopylov U, Paradis-Surprenant L, Almaimani M, Bitton A, Afif W, Lakatos PL, Bessissow T.

Dig Dis Sci. 2018 May;63(5):1302-1310. doi: 10.1007/s10620-017-4874-6. Epub 2017 Dec 14.

PMID:
29243105
44.

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

Gonczi L, Kurti Z, Golovics PA, Lovasz BD, Menyhart O, Seres A, Sumegi LD, Gal A, Ilias A, Janos P, Gecse KB, Bessisow T, Afif W, Bitton A, Vegh Z, Lakatos PL.

Dig Liver Dis. 2018 Jan;50(1):37-41. doi: 10.1016/j.dld.2017.09.137. Epub 2017 Oct 9.

PMID:
29107471
45.

Access to biologicals in Crohn's disease in ten European countries.

Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodszky V, Baji P, Crohn's Disease Research Group.

World J Gastroenterol. 2017 Sep 14;23(34):6294-6305. doi: 10.3748/wjg.v23.i34.6294.

46.

Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease.

Restellini S, Kherad O, Bessissow T, Ménard C, Martel M, Taheri Tanjani M, Lakatos PL, Barkun AN.

World J Gastroenterol. 2017 Aug 28;23(32):5994-6002. doi: 10.3748/wjg.v23.i32.5994. Review.

47.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.

Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL.

Inflamm Bowel Dis. 2017 Nov;23(11):1908-1915. doi: 10.1097/MIB.0000000000001237.

PMID:
28922253
48.

Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.

Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M.

World J Gastroenterol. 2017 Aug 7;23(29):5412-5421. doi: 10.3748/wjg.v23.i29.5412.

49.

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.

Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, Milassin Á, Fábián A, Szántó K, Végh Z, Kürti Z, Lakatos PL, Szepes Z, Molnár T.

Expert Opin Biol Ther. 2017 Nov;17(11):1325-1332. doi: 10.1080/14712598.2017.1363885. Epub 2017 Aug 18.

PMID:
28819991
50.

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.

Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL.

BMC Gastroenterol. 2017 Aug 8;17(1):97. doi: 10.1186/s12876-017-0654-1.

Supplemental Content

Loading ...
Support Center